The Enterprise Value as of December 2024 (TTM) for Ultragenyx Pharmaceutical Inc. (RARE) is 3.93B

According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.93B. This represents a change of -10.93% compared to the average of 4.42B of the last 4 quarters.

Ultragenyx Pharmaceutical Inc. (RARE) Historical Enterprise Value (quarterly & annually)

How has RARE Enterprise Value performed in the past?

The mean historical Enterprise Value of Ultragenyx Pharmaceutical Inc. over the last ten years is 3.35B. The current 3.93B Enterprise Value has changed 11.64% with respect to the historical average. Over the past ten years (40 quarters), RARE's Enterprise Value was at its highest in in the December 2020 quarter at 8.29B. The Enterprise Value was at its lowest in in the December 2014 quarter at 1.38B.

Ultragenyx Pharmaceutical Inc. (RARE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ultragenyx Pharmaceutical Inc. (RARE) Average Enterprise Value

How has RARE Enterprise Value performed in the past?

The current Enterprise Value of Ultragenyx Pharmaceutical Inc. (RARE) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Ultragenyx Pharmaceutical Inc. (RARE) Enterprise Value vs. Peers

How is RARE’s Enterprise Value compared to its peers?

Ultragenyx Pharmaceutical Inc.’s Enterprise Value is greater than X4 Pharmaceuticals, Inc. (79.21M), greater than Terns Pharmaceuticals, Inc. (234.86M), greater than Day One Biopharmaceuticals, Inc. (859.59M), greater than PDS Biotechnology Corporation (37.39M), greater than Inozyme Pharma, Inc. (215.58M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), less than Apellis Pharmaceuticals, Inc. (4.20B), less than Crinetics Pharmaceuticals, Inc. (4.74B), greater than Arvinas, Inc. (1.15B), less than Revolution Medicines, Inc. (7.90B), greater than Kura Oncology, Inc. (662.36M), greater than Acumen Pharmaceuticals, Inc. (103.15M), less than Incyte Corporation (12.19B), less than Alnylam Pharmaceuticals, Inc. (31.45B), less than United Therapeutics Corporation (15.08B),

Build a custom stock screener for Ultragenyx Pharmaceutical Inc. (RARE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ultragenyx Pharmaceutical Inc. (RARE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.